Recombinant Human VSIG3 Protein, Fc Tag, 100 µg

Background
VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.

Source
Recombinant Human VSIG3, Fc Tag (VS3-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Gly 241 (Accession # Q5DX21-1). Predicted N-terminus: Leu 23

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 49.7 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy"
Zhou, Khan, Huang et al
Front Immunol (2022) 13, 938470
(2)  "Structural Basis of VSIG3: The Ligand for VISTA"
Xie, Chen, Chen et al
Front Immunol (2021) 12, 625808
(3)  "VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy"
Yuan, Tatineni, Mahoney et al
Trends Immunol (2021) 42 (3), 209-227
Showing 1-3 of 6 papers.